<DOC>
	<DOCNO>NCT00257205</DOCNO>
	<brief_summary>This Phase 3 , multi-national , open-label , 2-arm randomize study patient surgically incurable metastatic melanoma receive prior chemotherapy , biochemotherapy treatment metastatic disease . The primary objective trial compare overall survival patient advance melanoma randomized receive CP-675,206 patient randomize receive either dacarbazine temozolomide ( investigator choice )</brief_summary>
	<brief_title>CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Surgically incurable melanoma , either Stage IV IIIC N3 status regional lymph node intransit satellite lesion . Serum lactic acid dehydrogenase ( LDH ) &lt; = 2 x ULN ECOG performance status 0 1 Received systemic therapy metastatic melanoma except postsurgical adjuvant treatment cytokine ( eg , alphainterferon GMCSF ) vaccines complete resection melanoma . History brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>